Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2023-10-21 06:00:00 ET Pfizer (NYSE: PFE) and Roche (OTC: RHHBY) have disappointed investors this year. Pfizer's shares have dropped more than 39% this year, and it's trading near its 52-week low. Roche has seen its stock drop by 19% and just hit a 52-week low on Oct. 19. ...
2023-10-20 09:38:08 ET Summary Solid balance sheet, higher DPS expected, and firepower. Roche is a company to have. COVID-19 has positively impacted the company, and now Wall Street is discounting lower sales estimates. However, Roche is growing nicely. Despite a challenging e...
2023-10-19 19:15:23 ET Summary Positive interim analysis from its phase 2 CALLIPER study achieved, showing a statistically significant reduction in neurofilament light chain (NfL) in progressive multiple sclerosis patients when given vidofludimus calcium. Vidofludimus calcium perf...
2023-10-19 12:10:28 ET More on BioNTech BioNTech: This Beaten Pandemic Star Will Capitalize On Oncology Treatments BioNTech: Renewed COVID Focus Might Spark Potential Share Price Boost BioNTech: Not Just Another Jab In The Arm Biggest stock movers today: Vist...
2023-10-19 08:31:42 ET More on PTC, Roche, etc. Recursion Pharmaceuticals: Wet Lab Meets Silicon, A Tale Of Two Bottom Lines Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche slips after in-line Q3 sales Roche in pact wit...
2023-10-19 07:26:46 ET More on Roche Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche: FX Drug But Positive Outlook Roche in pact with Monte Rosa to develop cancer and neuro drugs Data shows Genentech's Fenebrutinib redu...
– These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC) – – With about one in two people with early-stage NSCLC experiencing disease recurrence following surg...
2023-10-17 08:20:15 ET More on Monte Rosa Seeking Alpha’s Quant Rating on Monte Rosa Therapeutics Historical earnings data for Monte Rosa Therapeutics Financial information for Monte Rosa Therapeutics For further details see: Roche in pact with Mon...
2023-10-17 07:30:08 ET More on Gamida Cell Gamida Cell: The Treacherous Path To Profitability Gamida Cell Ltd. (GMDA) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Gamida Cell Historical earnings data for Gamida Cell Financia...
2023-10-13 12:38:42 ET More on Roche Holding Roche: 2023 Should Mark The Bottom Roche: FX Drug But Positive Outlook Roche's Ocrevus' 10-year data shows MS drug cuts disability progression AbbVie blood cancer therapy fails in Phase 3 trial For further ...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...